Abstract:Nonalcoholic fatty liver disease (NAFLD) is a growing global public health concern and becoming the leading cause of liver disease worldwide. The estimated global prevalence of NAFLD is similar to 25% depending on the country and the assessment method used to establish the diagnosis. Meta-analyses suggest that the highest prevalence is in the Middle East (31.8%) and South America (30.4%), and the lowest in Africa (13.5%). In the United States, between 75 and 100 million individuals were estimated to have NAFLD. This important disease is associated with increased incidence of liver-related deaths, hepatocarcinoma, and overall mortality. Fibrosis stage, among other histological characteristics, is the most critical factor in predicting all-cause and disease-specific mortality in NAFLD. The ability to detect fibrosis early in NAFLD patients is critical in controlling mortality associated with this highly prevalent disease. We present here an expert review on recent advances in novel blood biomarkers, for example, the Wisteria floribunda agglutinin-positive mac-2 binding protein (WFA(+)-M2BP), type IV collagen 7S, chitinase 3 like 1 (CHI3L1; YKL-40), and insulin-like growth factor-1 (IGF-1). Algorithms using multiple biomarkers such as alpha-2-macroglobulin, mir34a, YKL-40, and hemoglobin A1c (HbA1c; NIS4), enhanced liver fibrosis (ELF). Hepascore, FibroMeter, FibroTest, FIBROSpect, FIB-C3, and ADPAPT are also highlighted. Novel technologies such as tandem mass spectrometry to directly measure protein turnover rate of the key proteins involved in hepatic fibrosis, as an indicator of fibrogenesis, are also discussed. In conclusion, NAFLD is a growing global health problem that warrants long-term funding, research, and training of scholars across the fields of public health diagnostics, systems sciences, nutrition, hepatology, and clinical oncology.

Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Advances in Optical Imaging of Nonalcoholic Fatty Liver Disease

Recent Progress of Proteomics in Nonalcoholic Fatty Liver Disease*

Recent Progress in Small Molecule Fluorescent Probes for Imaging and Diagnosis of Non-Alcoholic Fatty Liver Disease

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future

Advances in Noninvasive Methods for Diagnosing Nonalcoholic Fatty Liver Disease

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

Update on Imaging-based Noninvasive Methods for Assessing Hepatic Steatosis in Nonalcoholic Fatty Liver Disease

High-fidelity Imaging of Fatty Liver in Vivo with a Fluorescent and Photoacoustic Dual-Mode Probe by Taking Advantage of the Liver “first Pass Effect”

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease: Current Evidence and Practice.

Recent Advances of Nanomaterials in Imaging Liver Fibrosis

Research Progress of Non-Invasive Diagnosis of Liver Fibrosis

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis.

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Progress in Serum Markers for Non-Alcoholic Fatty Liver Disease

Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications